# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-18-003326
Filing Date
2018-04-30
Accepted
2018-04-30 09:00:37
Documents
3
Period of Report
2018-06-13
Effectiveness Date
2018-04-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | a2235493zdef14a.htm | DEF 14A | 724024
2 | G29172BII001.GIF | g29172bii001.gif | GRAPHIC | 290078
3 | G29172BII002.GIF | g29172bii002.gif | GRAPHIC | 163952
| Complete submission text file | 0001047469-18-003326.txt |  | 1350691

Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-15006 | Film No.: 18786893
SIC: 2835 In Vitro & In Vivo Diagnostic Substances